Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
In cortisone reductase deficiency (CRD), activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2). This suggests a defect in the gene HSD11B1 encoding 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1), a primary regulator of tissue-specific glucocorticoid bioavailability. We identified intronic mutations in HSD11B1 that resulted in reduced gene transcription in three individuals with CRD. In vivo, 11beta-HSD1 catalyzes the reduction of cortisone to cortisol whereas purified enzyme acts as a dehydrogenase converting cortisol to cortisone. Oxo-reductase activity can be regained using a NADPH-regeneration system and the cytosolic enzyme glucose-6-phosphate dehydrogenase. But the catalytic domain of 11beta-HSD1 faces into the lumen of the endoplasmic reticulum (ER; ref. 6). We hypothesized that endolumenal hexose-6-phosphate dehydrogenase (H6PDH) regenerates NADPH in the ER, thereby influencing directionality of 11beta-HSD1 activity. Mutations in exon 5 of H6PD in individuals with CRD attenuated or abolished H6PDH activity. These individuals have mutations in both HSD11B1 and H6PD in a triallelic digenic model of inheritance, resulting in low 11beta-HSD1 expression and ER NADPH generation with loss of 11beta-HSD1 oxo-reductase activity. CRD defines a new ER-specific redox potential and establishes H6PDH as a potential factor in the pathogenesis of PCO…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This disorder is caused by inactivating mutations in H6PDH (590), which impair NADPH regeneration within the endoplasmic reticulum, rather than by mutations in the coding regions of HSD11B1.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [590]
In the citing paper
“Elevated anti-Müllerian hormone (AMH) levels have been a consistent hormonal finding associated with PCOM in healthy girls [90,91]”
From The Diagnosis of Polycystic Ovary Syndrome during Adolescence (2015) · cites this paper as [91]
In the citing paper
“Cortisone reductase deficiency (CRD) and apparent CRD (ACRD) are characterised by the failure to generate cortisol from inactive cortisone resulting in HPA axis activation and excessive ACTH-mediated adrenal androgen secretion, with ∼14 cases described clinically and biochemically in the literature (1, 2, 3, 4, 5, 6, 7, 8, 9) .”
From Novel H6PDH mutations in two girls with premature adrenarche: ‘apparent’ and ‘true’ CRD can be differentiated by urinary steroid profiling (2013) · cites this paper as [2]
In the citing paper
“CRD is caused by HSD11B1 deficiency (90) whereas ACRD results form a deficiency in the activity of H6PDH, which is essential for maintaining the reductive activity of HSD11B1 in vivo by the reduced form of NAD phosphate provision to the enzyme (91, 92).”
From Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism (2019) · cites this paper as [91]
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“) and adipose tissue (increased adipocyte differentiation and visceral obesit”
BackgroundCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Self-citationGlucose-6-phosphate Dehydrogenase
Löhr, G. W., & Waller, H. D. (1974) · Methods of Enzymatic Analysis · doi:10.1016/b978-0-12-091302-2.50026-8 · Cited by 1,190
Kotelevtsev, Y., Holmes, M. C., Burchell, A., Houston, P. M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C. R. W., Seckl, J. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14924 · Cited by 858
Digenic Retinitis Pigmentosa Due to Mutations at the Unlinked Peripherin/ RDS and ROM1 Loci
Kajiwara, K., Berson, E. L., & Dryja, T. P. (1994) · Science · doi:10.1126/science.8202715 · Cited by 775
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753
Self-citation11β-Hydroxysteroid Dehydrogenase
Stewart, P. M., & Krozowski, Z. S. (1997) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60646-9 · Cited by 718
Self-citationTriallelic Inheritance in Bardet-Biedl Syndrome, a Mendelian Recessive Disorder
Katsanis, N., Ansley, S. J., Badano, J. L., Eichers, E. R., Lewis, R. A., Hoskins, B. E., Scambler, P. J., Davidson, W. S., Beales, P. L., & Lupski, J. R. (2001) · Science · doi:10.1126/science.1063525 · Cited by 655 · cited 1×
“To our knowledge, however, there are only a few documented examples of a digenic triallelic trait: Bardet–Biedl syndrome, a heterogeneous disorder with symptoms including mental retardation, pigmentary retinopathy and obesit”
BackgroundKletzien, R. F., Harris, P. K. W., & Foellmi, L. A. (1994) · The FASEB Journal · doi:10.1096/fasebj.8.2.8119488 · Cited by 550
Cited by
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
Stincone, A., Prigione, A., Cramer, T., Wamelink, M. M. C., Campbell, K., Cheung, E., Olin‐Sandoval, V., Grüning, N., Krüger, A., Tauqeer Alam, M., et al. (2015) · Biological Reviews · doi:10.1111/brv.12140 · Cited by 1,576
“Several allelic variants of H6PDH mutations are known and result in hirsutism, oligomenorrhoea, obesity, acne and infertility (Jamieson et al., 1999; Draper et al., 2003; Lavery et al., 2008).”
BackgroundThe Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“The allele frequency for the 83557A/83597T-G haplotype was 14% in control populations (84).”
InfluentialSelf-citation11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Mendelian Inheritance in Man and Its Online Version, OMIM
McKusick, V. A. (2007) · The American Journal of Human Genetics · doi:10.1086/514346 · Cited by 739
Cooper, D. N., Krawczak, M., Polychronakos, C., Tyler-Smith, C., & Kehrer-Sawatzki, H. (2013) · Human Genetics · doi:10.1007/s00439-013-1331-2 · Cited by 645
“…nephronophthisis* NPHP1 NPHP6 Tory et al. (2007) Axenfeld–Rieger syndrome FOXC1 PITX2 Kelberman et al. (2011) Cortisone reductase deficiency HSD11B1 H6PD Draper et al. (2003) and San Millán et al. (2005) Hypertrophic cardiomyopathy* MYBPC3 TNNT2 or TNNI3 or MYH7 or TPM1 Richard et al. (2003),…”
TFOS DEWS II Sex, Gender, and Hormones Report
Sullivan, D. A., Rocha, E. M., Aragona, P., Clayton, J. A., Ding, J., Golebiowski, B., Hampel, U., McDermott, A. M., Schaumberg, D. A., Srinivasan, S., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.04.001 · Cited by 434
“The local production of cortisol depends on the activity of enzymes, such as the 11b-HSDs, which regulate the production of cortisol from cortisone, a reaction dependent on NADPH as cofactor [728], and vice versa.”
BackgroundVan Raalte, D. H., Ouwens, D. M., & Diamant, M. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02067.x · Cited by 439
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Escobar-Morreale, H. F., Luque-Ramírez, M., & San Millán, J. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0004 · Cited by 422
“Mutations in the genes encoding 11 -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase have been recently shown to cause cortisone reductase deficiency (163), and because the phenotypic features of affected women resemble those of PCOS, these genes should be considered candidates to explain the p…”
BackgroundArlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
Self-citationOxysterols: From cholesterol metabolites to key mediators
Mutemberezi, V., Guillemot-Legris, O., & Muccioli, G. G. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.002 · Cited by 335
The Human Obesity Gene Map: The 2004 Update
Pérusse, L., Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Snyder, E. E., & Bouchard, C. (2005) · Obesity Research · doi:10.1038/oby.2005.50 · Cited by 330
“Individuals with this disease carry mutations in both the HSD11B1 gene (encoding the enzyme 11beta-hydroxysteroid dehydrogenase type 1) and H6PD gene (encoding the endoluminal enzyme hexose-6-phosphate dehydrogenase, which regenerates NADPH, thereby increasing HSD11B1 activity) (”
BackgroundGlucocorticoids: exemplars of multi-tasking
Buckingham, J. C. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706456 · Cited by 276
“However, in vivo it appears to function solely as a reductase, relying on hexose-6-phosphate dehydrogenase (with which it is colocalised in the endoplasmic reticulum) to generate NADP(H) (Draper et al., 2003).”
BackgroundFlück, C. E., Meyer-Böni, M., Pandey, A. V., Kempná, P., Miller, W. L., Schoenle, E. J., & Biason-Lauber, A. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.009 · Cited by 248
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“It has been proposed that the level of 11 -HSD1 mRNA expression and total protein may not be the most-important determinant of net cortisol generation from cortisone, since the balance between reductase and dehydrogenase activities may be crucially dependent upon cofactor generation by hexose-6-phosphate dehydrogenase…”
InfluentialThe oligogenic properties of Bardet-Biedl syndrome
Katsanis, N. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh092 · Cited by 232
Li, Y., Chen, C., Ma, Y., Xiao, J., Luo, G., Li, Y., & Wu, D. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.046 · Cited by 198
Atanasov, A. G., Nashev, L. G., Schweizer, R. A. S., Frick, C., & Odermatt, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.065 · Cited by 210
Lavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207
Self-citationKannisto, K., Pietiläinen, K. H., Ehrenborg, E., Rissanen, A., Kaprio, J., Hamsten, A., & Yki-Järvinen, H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0153 · Cited by 205
Sandeep, T. C., Andrew, R., Homer, N. Z. M., Andrews, R. C., Smith, K., & Walker, B. R. (2005) · Diabetes · doi:10.2337/diabetes.54.3.872 · Cited by 205
Adrenal Corticosteroid Biosynthesis, Metabolism, and Action
Arlt, W., & Stewart, P. M. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.002 · Cited by 195
“Combined mutations in the genes encoding 11b-HSD1 and H6PDH explain the molecular basis for the putative 11b-HSD1 deficient state, cortisone reductase deficiency, an inherited form of polycystic ovary syndrome [65].”
BackgroundSelf-citation11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Self-citation11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Self-citationNebert, D. W., Zhang, G., & Vesell, E. S. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530801952864 · Cited by 181
“Cortisone reductase deficiency HSD11B1, H6PDH (Draper et al., 2003)”
Bánhegyi, G., Benedetti, A., Fulceri, R., & Senesi, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404159200 · Cited by 168
Bujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C., Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01718 · Cited by 165
“These patients carry coding-sequence mutations in the gene encoding H6PDH (H6PD) in association with intronic mutations in the 11 -HSD1 gene (HSD11B) that reduce gene transcription (Draper et al. 2003).”
BackgroundSelf-citationGlucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone
Løvås, K., Gjesdal, C. G., Christensen, M., Wolff, A. B., Almås, B., Svartberg, J., Fougner, K. J., Syversen, U., Bollerslev, J., Falch, J. A., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0880 · Cited by 163
Inhibition of 11ß-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target
Wamil, M., & Seckl, J. R. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.06.001 · Cited by 163
Premature adrenarche: novel lessons from early onset androgen excess
Idkowiak, J., Lavery, G. G., Dhir, V., Barrett, T. G., Stewart, P. M., Krone, N., & Arlt, W. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0223 · Cited by 158
Self-citationTissue Production of Cortisol by 11β‐Hydroxysteroid Dehydrogenase Type 1 and Metabolic Disease
WALKER, B. R., & ANDREW, R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.012 · Cited by 150
Genetic disorders of adipose tissue development, differentiation, and death.
Agarwal, A. K., & Garg, A. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115715 · Cited by 150
Hewitt, K. N., Walker, E. A., & Stewart, P. M. (2005) · Endocrinology · doi:10.1210/en.2005-0117 · Cited by 149
“candidates are likely to be involved (38).”
Self-citationPolycystic Ovary Syndrome in Adolescence
Buggs, C., & Rosenfield, R. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.04.005 · Cited by 157
“On rare occasions, adrenal hyperandrogenism can arise from cortisol resistance [88] or cortisone reductase (type 1 11β-hydroxysteroid dehydrogenase) deficiency [89].”
BackgroundSantos, C. X. C., Nabeebaccus, A. A., Shah, A. M., Camargo, L. L., Filho, S. V., & Lopes, L. R. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5262 · Cited by 140
“The ER is linked to different aspects of lipid metabolism with a role in the synthesis of phospholipids, and triacylglycerol (27, 29), and the ER lumen also contains some enzymes of gluco-neogenesis and fatty acid oxidation.”
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
Self-citationAn update of genetic basis of PCOS pathogenesis
Crespo, R. P., Bachega, T. A. S. S., Mendonça, B. B., & Gomes, L. G. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000049 · Cited by 138
“In11β-HSD type I deficiency, cortisone is not convert into cortisol, with a consequent elevation of ACTH, which stimulates androgen production, leading to the PCOS phenotype (14).”
BackgroundGlucocorticoid-mediated mineralocorticoid receptor activation and hypertension
Frey, F. J., Odermatt, A., & Frey, B. M. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000133976.32559.b0 · Cited by 137
Seckl, J. R., & Walker, B. R. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.09.007 · Cited by 154
11&Bgr;-Hydroxysteroid Dehydrogenase Type 1 and Obesity
Morton, N. M., & Seckl, J. R. (2008) · Frontiers of Hormone Research · doi:10.1159/000115363 · Cited by 134
Endoplasmic reticulum: A metabolic compartment
Csala, M., Bánhegyi, G., & Benedetti, A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.050 · Cited by 125
“Nevertheless, under physiological conditions in the ER lumen the native substrates for H6PDH are believed to be G6P and NADP+ [21].”
BackgroundInfluential11?-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes
Stulnig, T. M., & Waldh�usl, W. (2004) · Diabetologia · doi:10.1007/s00125-003-1284-4 · Cited by 140
“[Diabetologia (2004) 47:1–11] Keywords Hydroxysteroid dehydrogenase · hydrocortisone · glucocorticoids · visceral obesity · diabetes mellitus · insulin resistance · adipose tissue · intra-abdominal fat · pituitary-adrenal system · Cushing’s syndrome Received: 10 June 2003 / Revised: 29 October 2003 Published online: 3…”
BackgroundInfluentialGe, R., Dong, Q. G., Niu, E.-M., Sottas, C. M., Hardy, D. O., Catterall, J. F., Latif, S. A., Morris, D. J., & Hardy, M. P. (2005) · Endocrinology · doi:10.1210/en.2005-0046 · Cited by 121
Sequencing EVC and EVC2 identifies mutations in two-thirds of Ellis–van Creveld syndrome patients
Tompson, S. W. J., Ruiz-Perez, V. L., Blair, H. J., Barton, S., Navarro, V., Robson, J. L., Wright, M. J., & Goodship, J. A. (2006) · Human Genetics · doi:10.1007/s00439-006-0237-7 · Cited by 121
“There have also been examples of triallelic inheritance, which is a requirement for three mutant alleles from two gene pairs, Wrst reported in Bardet Biedl syndrome and subsequently in cortisone reductase deWciency (Katsanis et al. 2001; Draper et al. 2003).”
BackgroundAgarwal, A. K., & Auchus, R. J. (2005) · Endocrinology · doi:10.1210/en.2005-0061 · Cited by 112
“These subjects have intronic polymorphisms in the HSD11B1 gene that reduce expression and, more importantly, mutations in the H6PDH gene that impair intralumenal NADPH regeneration (45).”
BackgroundPereira, C., Azevedo, I., Monteiro, R., & Martins, M. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01582.x · Cited by 126
Nair, S., Lee, Y. H., Lindsay, R. S., Walker, B. R., Tataranni, P. A., Bogardus, C., Baier, L. J., & Permana, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1407-6 · Cited by 124
“Both SNPs 4 and 5 act as intronic enhancers that modulate 11β-HSD1 expression and activity [31].”
Background11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome
Wake, D. J., & Walker, B. R. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.11.015 · Cited by 124
Morton, N. M., Ramage, L., & Seckl, J. R. (2004) · Endocrinology · doi:10.1210/en.2003-1674 · Cited by 111
“Potential posttrancriptional mechanisms leading to inhibition of 11 -HSD-1 reductase activity include down-regulation of nicotinamide adenine dinucleotidephosphate cosubstrate generating enzymes (33) and stimulation of the lipid activated protein kinase C (34).”
BackgroundFunctional modules, mutational load and human genetic disease
Zaghloul, N. A., & Katsanis, N. (2010) · Trends in Genetics · doi:10.1016/j.tig.2010.01.006 · Cited by 104
Hosfield, D. J., Wu, Y., Skene, R. J., Hilgers, M., Jennings, A., Snell, G. P., & Aertgeerts, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411104200 · Cited by 102
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
Knezevic, C. E., Wright, G., Remsing Rix, L. L., Kim, W., Kuenzi, B. M., Luo, Y., Watters, J. M., Koomen, J. M., Haura, E. B., Monteiro, A. N., et al. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.10.011 · Cited by 100
“To determine the biochemical consequence of this interaction, we performed an in vitro H6PD activity assay, adapted from a literature assay that used hepatic cell lysates (Draper et al., 2003), with total lysate from both parental and H6PD-overexpressing HEK293 cells (Figure 5C).”
InfluentialStewart, P. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490163 · Cited by 105
Self-citationRapid mechanisms of glucocorticoid signaling in the Leydig cell☆
Hu, G., Lian, Q., Lin, H., LATIF, S., Morris, D. J., Hardy, M. P., & GE, R. (2008) · Steroids · doi:10.1016/j.steroids.2007.12.020 · Cited by 104
“[58] Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al.”
Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness
Nozu, K., Inagaki, T., Fu, X. J., Nozu, Y., Kaito, H., Kanda, K., Sekine, T., Igarashi, T., Nakanishi, K., Yoshikawa, N., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.052944 · Cited by 100
Lavery, G. G., Walker, E. A., Tiganescu, A., Ride, J. P., Shackleton, C. H. L., Tomlinson, J. W., Connell, J. M. C., Ray, D. W., Biason-Lauber, A., Malunowicz, E. M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0743 · Cited by 95
“Others have shown thatmicelackingHSD11B1lackbothactivities(10).Previously, we identified sequence variants in H6PD and HSD11B1 in patients with CRD ( 3 ), but subsequent large-scale populationbasedstudiesfromthreecentersincludingourownindicatedthat thesewerepolymorphicvariantsratherthandisease-causingmutations, with p…”
BackgroundMethodInfluentialSelf-citationYazawa, T., Uesaka, M., Inaoka, Y., Mizutani, T., Sekiguchi, T., Kajitani, T., Kitano, T., Umezawa, A., & Miyamoto, K. (2008) · Endocrinology · doi:10.1210/en.2007-1015 · Cited by 95
Weight Loss Increases 11β-Hydroxysteroid Dehydrogenase Type 1 Expression in Human Adipose Tissue
Tomlinson, J. W., Moore, J. S., Clark, P. M. S., Holder, G., Shakespeare, L., & Stewart, P. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031376 · Cited by 90
“We have recently defined the molecular basis for the disease which is caused by intronic mutations within the HSD11B1 gene that decrease transcription in combination with mutations in hexose-6-phosphate dehydrogenase, an enzyme that is believed to provide NADPH for 11β-HSD1 which is essential for reductase activity (3…”
Self-citationAdrenocortical dysregulation as a major player in insulin resistance and onset of obesity
Roberge, C., Carpentier, A. C., Langlois, M.-F., Baillargeon, J.-P., Ardilouze, J.-L., Maheux, P., & Gallo-Payet, N. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00516.2007 · Cited by 89
“The types 1 and 2 steroid-5 -reductases (SRD5A1 and SRD5A2) are also involved in the conversion of adrenal precursors and testosterone into 5 -dihydrotestosterone (DHT), the most potent natural androgen, and may thus be involved in increased production of androgens observed in AJP-Endocrinol Metab • VOL 293 • DECEMBER…”
InfluentialVéniant, M. M., Hale, C., Hungate, R. W., Gahm, K. H., Emery, M. G., Jona, J. A., Joseph, S., Adams, J., Hague, A. B., Moniz, G. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100242d · Cited by 85
Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach
Nautiyal, H., Imam, S. S., Alshehri, S., Ghoneim, M. M., Afzal, M., Alzarea, S. I., Güven, E., Al-Abbasi, F. A., & Kazmi, I. A. (2022) · Biomedicines · doi:10.3390/biomedicines10030540 · Cited by 100
Uncoupled Redox Systems in the Lumen of the Endoplasmic Reticulum
Piccirella, S., Czegle, I., Lizák, B., Margittai, É., Senesi, S., Papp, E., Csala, M., Fulceri, R., Csermely, P., Mandl, J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509406200 · Cited by 78
Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome
Mariniello, B., Ronconi, V., Rilli, S., Bernante, P., Boscaro, M., Mantero, F., & Giacchetti, G. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02228 · Cited by 74
Gambineri, A., Vicennati, V., Genghini, S., Tomassoni, F., Pagotto, U., Pasquali, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2222 · Cited by 75
“These mechanisms appear to operate in the rare syndrome of cortisone reductase deficiency, characterized by an inability to convert cortisone to cortisol (12, 13).”
BackgroundInfluentialCortisol excess in chronic kidney disease – A review of changes and impact on mortality
Sagmeister, M. S., Harper, L., & Hardy, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1075809 · Cited by 93
“However, this association has not been confirmed in other genome-wide association studies for glomerular filtration rate (100), and no renal phenotype has been reported for the small number of adults with genetic 11b-HSD1 deficiency (cortisone reductase deficiency) described in the literature (28, 101).”
ResultTomlinson, J., & Stewart, P. M. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0023 · Cited by 82
“and this is supplied by another tightly associated endolumenal enzyme, hexose-6-phosphate dehydrogenase (H6PDH”
BackgroundSelf-citationFreeman, L., Hewison, M., Hughes, S. V., Evans, K. N., Hardie, D., Means, T. K., & Chakraverty, R. (2005) · Blood · doi:10.1182/blood-2005-01-0186 · Cited by 71
Self-citationEvidence That the 11 β-Hydroxysteroid Dehydrogenase (11 β-HSD1) Is Regulated by Pentose Pathway Flux
McCormick, K. L., Wang, X., & Mick, G. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506026200 · Cited by 72
11β-hydroxysteroid dehydrogenases: A growing multi-tasking family
Gómez-Sánchez, E. P., & Gómez-Sánchez, C. E. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111210 · Cited by 89
“The inability to convert cortisone to cortisol results in the increased metabolic clearance rate of cortisol, excreted primarily as cortisone and cortisone metabolites, and increased ACTH secretion to maintain normal circulating cortisol concentrations that results in ACTH-mediated androgen excess.”
BackgroundInfluentialSironi, M., Menozzi, G., Comi, G. P., Cagliani, R., Bresolin, N., & Pozzoli, U. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi257 · Cited by 78
“HSD11B1 3 Transcriptional enhancer caccaagagcttttgggaggagaatgggaaaggtatcaaccccagatga — Point mutations cause cortisone reductase deficiency if combined with H6PD mutations (42)”
BackgroundEnvironmental Pollutants and Hydroxysteroid Dehydrogenases
Ye, L., Guo, J., & Ge, R. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800095-3.00013-4 · Cited by 73
Triallelic inheritance: a bridge between Mendelian and multifactorial traits
Eichers, E., Lewis, R. A., Katsanis, N., & Lupski, J. (2004) · Annals of Medicine · doi:10.1080/07853890410026214 · Cited by 67
Gomez-Sanchez, E. P., Romero, D. G., de Rodriguez, A. F., Warden, M. P., Krozowski, Z., & Gomez-Sanchez, C. E. (2008) · Endocrinology · doi:10.1210/en.2007-0328 · Cited by 66
“The obligate relationship between reductase activity of the 11 HSD1 enzyme and H6PDH for reductase activity by the 11 -HSD1 was suggested by a study of cortisol reductase deficiency in humans (44) and confirmed by elegant experiments using differentiating adipocytes (45), as well as a H6PDH knockout mouse (14).”
Background17-Hydroxyprogesterone in children, adolescents and adults
Honour, J. W. (2014) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563214529748 · Cited by 60
Why is 11β-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen?
Odermatt, A., Atanasov, A. G., Balázs, Z., Schweizer, R. A. S., Nashev, L. G., Schuster, D., & Langer, T. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.11.040 · Cited by 83
San Millán, J. L., Botella-Carretero, J. I., Álvarez-Blasco, F., Luque-Ramírez, M., Sancho, J., Moghetti, P., & Escobar-Morreale, H. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1523 · Cited by 65
Hexose-6-phosphate dehydrogenase in the endoplasmic reticulum
Senesi, S., Csala, M., Marcolongo, P., Fulceri, R., Mandl, J., Bánhegyi, G., & Benedetti, A. (2009) · Biological Chemistry · doi:10.1515/bc.2009.146 · Cited by 64
Glucocorticoids and gut bacteria: “The GALF Hypothesis” in the metagenomic era
Morris, D. J., & Ridlon, J. M. (2017) · Steroids · doi:10.1016/j.steroids.2017.06.002 · Cited by 68
Schimke immunoosseous dysplasia: suggestions of genetic diversity
Clewing, J. M., Fryssira, H., Goodman, D., Smithson, S., Sloan, E. A., Lou, S., Huang, Y., Choi, K., Lücke, T., Alpay, H., et al. (2006) · Human Mutation · doi:10.1002/humu.20432 · Cited by 62
“For example, digenic triallelic inheritance has been described for Bardet-Biedl syndrome [Katsanis et al., 2001], familial hypercholanemia [Carlton et al., 2003], cortisone reductase deficiency [Draper et al., 2003], and hemochromatosis [Merryweather-Clarke et al., 2003].”
BackgroundHenschkowski, J., Stuck, A. E., Frey, B. M., Gillmann, G., Dick, B., Frey, F. J., & Mohaupt, M. G. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.152 · Cited by 58
Stomby, A., Andrew, R., Walker, B. R., & Olsson, T. (2014) · Diabetologia · doi:10.1007/s00125-014-3228-6 · Cited by 68
Hu, X., Kohler, K. M., Falick, A. M., Moore, A., Jones, P. R., Sparkman, O. D., & Vierra, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412316200 · Cited by 58
Atanasov, A. G., Nashev, L. G., Gelman, L., Legeza, B., Sack, R., Portmann, R., & Odermatt, A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.03.001 · Cited by 58
“H6PDH leads to the stimulation of the 11β-HSD1-dependent formation of active glucocorticoids [23–27].”
BackgroundModulation of glucocorticoid action and the treatment of type-2 diabetes
Tomlinson, J., & Stewart, P. M. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.003 · Cited by 59
Self-citationWalker, B. R., & Seckl, J. R. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.771 · Cited by 57
“It has been proposed that the level of 11HSD1 mRNA expression and total protein may not be the most important determinant of net cortisol generation from cortisone, since the balance between reductase and dehydrogenase activities may be crucially dependent upon cofactor generation by hexose-6-phosphate dehydrogenase […”
Influentialvan Rossum, E. F. C., Russcher, H., & Lamberts, S. W. J. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.10.009 · Cited by 56
Sixty Years after Hench—Corticosteroids and Chronic Inflammatory Disease
Edwards, C. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2879 · Cited by 51
“6-phosphate dehydrogenase (H6PDH), which produces the cofactor for 11 -HSD1, nicotinamide adenine dinucleotide phosphate (18).”
BackgroundWalker, B. R. (2007) · Proceedings of the Nutrition Society · doi:10.1017/s002966510700523x · Cited by 54
“It appears most likely that inactivating mutations in hexose-6-phosphate dehydrogenase (Draper et al. 2003), an enzyme closely associated with 11b-HSD1 in the lumen of the endoplasmic reticulum, result in an inadequate supply of NADPH cofactor for 11b-HSD1 reductase activity.”
BackgroundQuinkler, M., Zehnder, D., Lepenies, J., Petrelli, M. D., Moore, J. S., Hughes, S. V., Cockwell, P., Hewison, M., & Stewart, P. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01954 · Cited by 51
Self-citationThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Clinical and Biochemical Consequences of P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2011) · Endocrine Development · doi:10.1159/000321221 · Cited by 52
Csala, M., Kereszturi, É., Mandl, J., & Bánhegyi, G. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4227 · Cited by 53
Liu, Y., Nakagawa, Y., Wang, Y., Liu, L., Du, H., Wang, W., Ren, X., Lutfy, K., & Friedman, T. C. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0004 · Cited by 53
“Our findings are consistent with recent studies reporting that lack of G6P availability to H6PDH is associated with impaired hepatic 11b-HSD1 reductase activity in hypoglycemic mice ( Chou et al. 2002 ).”
BackgroundResultInfluentialThe potential role of genes in nonalcoholic fatty liver disease
Day, C. P. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.001 · Cited by 53
Lavery, G. G., Idkowiak, J., Sherlock, M., Bujalska, I., Ride, J. P., Saqib, K., Hartmann, M. F., Hughes, B., Wudy, S. A., De Schepper, J., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0628 · Cited by 50
Self-citationGlucocorticoid Excess in Bone and Muscle
Sato, A. Y., Peacock, M., & Bellido, T. (2018) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-018-9242-3 · Cited by 56
“Absence of the phenotype also occurs if the 11βhydroxysteroid dehydrogenase type1 (11β-HSD1), which converts inactive to active GC metabolites, is defective [13, 15, 16], or if there is a defect in a coenzyme, H6PDH [17, 18].”
Metadata
- Authors
- Draper, N., Walker, E. A., Bujalska, I. J., Tomlinson, J. W., Chalder, S. M., Arlt, W., Lavery, G. G., Bedendo, O., Ray, D. W., Laing, I., Malunowicz, E., White, P. C., Hewison, M., Mason, P. J., Connell, J. M., Shackleton, C. H. L., & Stewart, P. M.
- Affiliations
- Queen Elizabeth Hospital Birmingham (GB)
- University of Manchester (GB)
- Manchester Royal Infirmary (GB)
- The University of Texas Southwestern Medical Center (US)
- Hammersmith Hospital (GB)
- University of Glasgow (GB)
- UCSF Benioff Children's Hospital (US)
- Corresponding author
- Stewart, Paul M
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-07-13
- Volume
- 34
- Issue
- 4
- Pages
- 434-439
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2104167472
- Semantic Scholar
- cfd40673c0802069d07c6edccb428ba58392c928
- Cited by
- 285
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 5 · 2014: 12 · 2013: 14 · 2012: 22
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- University of Birmingham
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- 11β-hydroxysteroid dehydrogenase type 1, hexose-6-phosphate dehydrogenase, intronic variants, NADPH regeneration, endoplasmic reticulum, glucocorticoid metabolism, ACTH, hyperandrogenism, polycystic ovary syndrome, digenic inheritance, gene transcription
- MeSH terms
- Amino Acid Sequence, Base Sequence, Carbohydrate Dehydrogenases, Cell Line, Cortisone Reductase, Endoplasmic Reticulum, Exons, Female, Humans, Hydroxysteroid Dehydrogenases, Male, Molecular Sequence Data, Mutation, NADP, Oxidation-Reduction, Phenotype, Polycystic Ovary Syndrome, RNA, Messenger, Transfection, Case-Control Studies, Sequence Homology, Amino Acid, DNA, Complementary, 11-beta-Hydroxysteroid Dehydrogenase Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.